At Aurigene Pharmaceutical Services, we design strategic approaches to improve druggability by improving bioavailability and ADME parameters. We provide end-to-end solutions from discovery to manufacturing.
Our portfolio of peptides ranges from simple side-chain modification upto 80 amino acids to backbone and side-chain modified peptides and derivatized peptides.
We offer efficient and environmentally friendly state-of-the-art microwave synthesis. This enables high throughput synthesis of difficult-to-do peptide chemistry (e.g., synthesis of peptides with hindered and N-alkylated amino acids). We are well equipped with peptide synthesizers including CEM automated microwave peptide synthesizer.
Expertise in peptide optimization to improve pharmacological properties
Core competencies ranging from simple linear peptides to complex forms
One-stop solution from Discovery, Development to Manufacturing of Peptides.
Synthesis, scale-up and peptide discovery capabilities
Advanced analytical tools for peptide characterization
Working with major pharmaceutical companies from USA and Europe.
Large manufacturing capabilities in US FDA inspected sites
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
There are three major synthesis routes for peptides, solid phase peptide synthesis (SPPS), solution/liquid phase peptide synthesis (LPPS) and hybrid phase peptide synthesis. Hybrid phase peptide synthesis is a combination of solid and liquid peptide synthesis methods.
Microwave assisted peptide synthesis is one of the most efficient and environmentally friendly method, it enables high throughput synthesis of difficult to make peptides and reduces cycle times to 4 minutes while minimizing the required amount of solvent by 90%.
Peptide synthesis depends on the required sequence length, complexity, purity and quantity of the peptide, it usually ranges from few days for a peptide to few weeks depending on these variables.
Aurigene has expertise in development and manufacturing of peptides via solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) procedures.
The strategies involved are
Depending on the requirements, short and longer peptides can be synthesized between 5mer-50mer. SPPS approach is preferable to generate longer peptides Ex: 50 mer (with 50 amino acids).
Long chain peptides can be preferably synthesized following Solid Phase Peptide Synthesis (SPPS) procedures. Depending on the length and complexity of the peptide convergent or hybrid approaches can be adopted.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.